Literature DB >> 28475004

Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway.

Li Zheng1, Jiangtao Chen1, Zhongyong Zhou1, Zhikuan He1.   

Abstract

Long non-coding RNA HOXD-AS1 (HOXD cluster antisense RNA 1) has been demonstrated to be closely associated with the progression of several tumors. However, the biological function of HOXD-AS1 and the underlying molecular mechanism in gastric cancer are still unclear. The expression of HOXD-AS1 in gastric cancer cell lines was evaluated by quantitative real-time polymerase chain reaction. The association of HOXD-AS1 expression and clinical parameters was statistically analyzed by chi-square test. Cell viability, colony formation capacity, and phosphorylation of Janus kinase 2 and signal transducer and activator of transcription 3 in treated SGC-7901 and BGC-823 cells were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, colony formation assay, and western blot analysis, respectively. The results indicated that HOXD-AS1 was significantly upregulated in gastric cancer cells and clinically involved in tumor size, invasion depth, tumor-node-metastasis stages, regional lymph nodes, lymphatic metastasis, as well as distant metastasis. HOXD-AS1 knockdown dramatically inhibited gastric cancer cell proliferation, colony formation capacity, and phosphorylation of Janus kinase 2 and signal transducer and activator of transcription 3 in vitro. In addition, HOXD-AS1 overexpression significantly promoted gastric cancer cell proliferation and colony formation capacity, whereas both Janus kinase small interfering RNAs and Janus kinase 2 inhibitor AG490 overturned these effects. Furthermore, xenograft assays confirmed the biological function of HOXD-AS1 in vivo. Taken together, our data elucidate that knockdown of HOXD-AS1 dramatically suppresses gastric cancer cell growth by inactivating the Janus kinase 2/signal transducer and activator of transcription 3 pathway in vitro and in vivo, contributing to a better understanding of gastric cancer pathogenesis and providing a possible theoretical foundation for long non-coding RNA-directed diagnosis and therapy against this disease.

Entities:  

Keywords:  HOXD cluster antisense RNA 1; Janus kinase 2/signal transducer and activator of transcription 3; Long non-coding RNA; gastric cancer

Mesh:

Substances:

Year:  2017        PMID: 28475004     DOI: 10.1177/1010428317705335

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  16 in total

1.  LncRNA HOXD-AS1 promotes melanoma cell proliferation and invasion by suppressing RUNX3 expression.

Authors:  Hailin Zhang; Ming Bai; Ang Zeng; Loubin Si; Nanze Yu; Xiaojun Wang
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  There and Back Again: Hox Clusters Use Both DNA Strands.

Authors:  Elena L Novikova; Milana A Kulakova
Journal:  J Dev Biol       Date:  2021-07-15

3.  HOXD-AS1 promotes cell proliferation, migration and invasion through miR-608/FZD4 axis in ovarian cancer.

Authors:  Yanyan Wang; Wenjuan Zhang; Yuyan Wang; Shanfeng Wang
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

4.  LncRNA HOXD-AS1 promotes the metastasis of human hepatocellular carcinoma via modulating miR-326/SLC27A4.

Authors:  Wenbin Ji; Qunfeng Wang; Jian Yang
Journal:  Cancer Cell Int       Date:  2020-05-12       Impact factor: 5.722

Review 5.  Long non-coding RNAs involved in metastasis of gastric cancer.

Authors:  Meng-Ting Lin; Hao-Jun Song; Xiao-Yun Ding
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

6.  Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review.

Authors:  Fuhong Zhang; Xiaowan Chen; Kehu Xi; Zhiqiang Qiu; Youhu Wang; Yan Gui; Yun Hou; Kangbing Chen; Xiaobing Zhang
Journal:  Onco Targets Ther       Date:  2018-11-05       Impact factor: 4.147

7.  HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2.

Authors:  Yafei Ye; Shengnan Yang; Yanping Han; Jingjing Sun; Lijuan Xv; Lina Wu; Liang Ming
Journal:  Open Biol       Date:  2019-09-25       Impact factor: 6.411

8.  A six-long non-coding RNAs signature as a potential prognostic marker for survival prediction of ER-positive breast cancer patients.

Authors:  Lei Zhong; Ge Lou; Xinglu Zhou; Youyou Qin; Lin Liu; Wenqian Jiang
Journal:  Oncotarget       Date:  2017-07-01

9.  Long non-coding RNA HOXD-AS1 promotes tumor progression and predicts poor prognosis in colorectal cancer.

Authors:  Xiang Li; Xinhan Zhao; Binhui Yang; Yuqing Li; Tao Liu; Linyuan Pang; Zhigang Fan; Wu Ma; Zhongqiu Liu; Zeng Li
Journal:  Int J Oncol       Date:  2018-05-09       Impact factor: 5.650

Review 10.  STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Sima Orouei; Vahideh Zarrin; Ebrahim Rahmani Moghadam; Amirhossein Zabolian; Shima Mohammadi; Kiavash Hushmandi; Yashar Gharehaghajlou; Pooyan Makvandi; Masoud Najafi; Reza Mohammadinejad
Journal:  Biology (Basel)       Date:  2020-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.